Scientific Reports (May 2017)

Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates

  • Fernando Bartolome,
  • Noemi Esteras,
  • Angeles Martin-Requero,
  • Claire Boutoleau-Bretonniere,
  • Martine Vercelletto,
  • Audrey Gabelle,
  • Isabelle Le Ber,
  • Tadashi Honda,
  • Albena T. Dinkova-Kostova,
  • John Hardy,
  • Eva Carro,
  • Andrey Y. Abramov

DOI
https://doi.org/10.1038/s41598-017-01678-4
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Abnormal mitochondrial function has been found in patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Mutations in the p62 gene (also known as SQSTM1) which encodes the p62 protein have been reported in both disorders supporting the idea of an ALS/FTD continuum. In this work the role of p62 in energy metabolism was studied in fibroblasts from FTD patients carrying two independent pathogenic mutations in the p62 gene, and in a p62-knock-down (p62 KD) human dopaminergic neuroblastoma cell line (SH-SY5Y). We found that p62 deficiency is associated with inhibited complex I mitochondrial respiration due to lack of NADH for the electron transport chain. This deficiency was also associated with increased levels of NADPH reflecting a higher activation of pentose phosphate pathway as this is accompanied with higher cytosolic reduced glutathione (GSH) levels. Complex I inhibition resulted in lower mitochondrial membrane potential and higher cytosolic ROS production. Pharmacological activation of transcription factor Nrf2 increased mitochondrial NADH levels and restored mitochondrial membrane potential in p62-deficient cells. Our results suggest that the phenotype is caused by a loss-of-function effect, because similar alterations were found both in the mutant fibroblasts and the p62 KD model. These findings highlight the implication of energy metabolism in pathophysiological events associated with p62 deficiency.